MX2011008952A - Activadores de guanilato ciclasa solubles. - Google Patents
Activadores de guanilato ciclasa solubles.Info
- Publication number
- MX2011008952A MX2011008952A MX2011008952A MX2011008952A MX2011008952A MX 2011008952 A MX2011008952 A MX 2011008952A MX 2011008952 A MX2011008952 A MX 2011008952A MX 2011008952 A MX2011008952 A MX 2011008952A MX 2011008952 A MX2011008952 A MX 2011008952A
- Authority
- MX
- Mexico
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- cyclase activators
- compounds
- dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a compuestos que tienen la fórmula estructural I (ver fórmula (I)) y a sales farmacéuticamente aceptables de los mismos que son activadores de laguanilato ciclasa soluble; los compuestos son útiles para el tratamiento o prevención de enfermedades cardiovasculares, disfunción endotelial, disfunción diastólica, aterosclerosis, hipertensión, hipertensión pulmonar, angina de pecho, trombosis, reestenosis, infarto de miocardio, apoplejías, insuficiencia cardiaca, hipertonía pulmonar, disfunción eréctil, asma bronquial, insuficiencia renal crónica, diabetes o cirrosis del hígado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20864809P | 2009-02-26 | 2009-02-26 | |
PCT/US2010/024853 WO2010099054A2 (en) | 2009-02-26 | 2010-02-22 | Soluble guanylate cyclase activators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008952A true MX2011008952A (es) | 2011-09-27 |
Family
ID=42410011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008952A MX2011008952A (es) | 2009-02-26 | 2010-02-22 | Activadores de guanilato ciclasa solubles. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8507512B2 (es) |
EP (1) | EP2401265B1 (es) |
JP (1) | JP5411300B2 (es) |
KR (1) | KR20110133034A (es) |
CN (1) | CN102414194A (es) |
AR (1) | AR075609A1 (es) |
AU (1) | AU2010218224B2 (es) |
BR (1) | BRPI1008793A2 (es) |
CA (1) | CA2753434C (es) |
CO (1) | CO6430463A2 (es) |
IL (1) | IL214559A0 (es) |
MX (1) | MX2011008952A (es) |
RU (1) | RU2011138970A (es) |
TW (1) | TW201035077A (es) |
WO (1) | WO2010099054A2 (es) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009032249A1 (en) * | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
MX2011008952A (es) | 2009-02-26 | 2011-09-27 | Merck Sharp & Dohme | Activadores de guanilato ciclasa solubles. |
US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
EP2683710B1 (en) * | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
EP2766360B1 (en) | 2011-08-12 | 2017-07-12 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
WO2013192125A1 (en) * | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
DK2892891T3 (da) | 2012-09-07 | 2019-10-14 | Boehringer Ingelheim Int | Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer |
CN109369635B (zh) | 2013-03-15 | 2023-06-30 | 赛克里翁治疗有限公司 | 化合物或其药学上可接受的盐及其应用和药物组合物 |
AU2014316690B2 (en) * | 2013-09-05 | 2017-08-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
US9611278B2 (en) | 2013-12-11 | 2017-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US20160311826A1 (en) | 2013-12-11 | 2016-10-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
TW201625584A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625586A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625601A (zh) * | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
DK3172202T3 (da) | 2014-07-22 | 2020-04-27 | Boehringer Ingelheim Int | Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase |
CN105980373A (zh) * | 2014-09-05 | 2016-09-28 | 葛兰素史密斯克莱知识产权发展有限公司 | 新的可溶性鸟苷酸环化酶活化剂及它们的用途 |
US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US20170291889A1 (en) | 2014-09-17 | 2017-10-12 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
EP3194386A2 (en) | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
CN106687456B (zh) * | 2014-09-19 | 2019-12-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 可溶性鸟苷酸环化酶活化剂及它们的用途 |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
EP3303342B1 (en) | 2015-05-27 | 2021-03-17 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
PE20180799A1 (es) | 2015-06-15 | 2018-05-09 | Glaxosmithkline Ip Dev Ltd | Reguladores de nrf2 |
AU2016280236B2 (en) | 2015-06-15 | 2019-02-07 | Astex Therapeutics Limited | Nrf2 regulators |
US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
EP3371167A1 (en) * | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
KR20180095594A (ko) * | 2015-12-18 | 2018-08-27 | 노파르티스 아게 | 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도 |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
CA3029374A1 (en) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Phosphorus prodrugs of sgc stimulators |
US10889577B2 (en) | 2016-07-07 | 2021-01-12 | Cyclerion Therapeutics, Inc. | Solid forms of an sGC stimulator |
BR112019004468A2 (pt) | 2016-09-02 | 2019-05-28 | Ironwood Pharmaceuticals Inc | estimulantes de sgc |
CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
CN110267949A (zh) | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
EP3538096B1 (en) | 2016-11-08 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2019055859A1 (en) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
US11897887B2 (en) | 2017-12-19 | 2024-02-13 | Tisento Therapeutics Inc. | sGC stimulators |
MX2023004857A (es) | 2018-03-07 | 2023-11-24 | Cyclerion Therapeutics Inc | Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). |
US20210052528A1 (en) | 2018-04-30 | 2021-02-25 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
EP3820476A1 (en) | 2018-07-11 | 2021-05-19 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of mitochonrial disorders |
BR112021009958A2 (pt) | 2018-11-28 | 2021-08-17 | Topadur Pharma Ag | modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos |
WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
WO2021202546A1 (en) | 2020-03-31 | 2021-10-07 | Cyclerion Therapeutics, Inc. | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
EP4326722A1 (en) | 2021-04-20 | 2024-02-28 | Tisento Therapeutics Inc. | Sgc stimulators |
US20240207265A1 (en) | 2021-04-20 | 2024-06-27 | Tisento Therapeutics Inc. | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS |
WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
WO2024086182A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
WO2024086179A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB876526A (en) | 1957-12-24 | 1961-09-06 | Geigy Ag J R | Process for the production of new aminobenzoic acid derivatives and their use in pest control |
US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
DE4011361A1 (de) | 1990-04-07 | 1991-10-10 | Bayer Ag | 2-aryl-6-hetarylpyridin-derivate |
US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
BR0207975A (pt) | 2001-03-15 | 2004-06-15 | Basf Ag | Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos |
DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
US7241803B2 (en) | 2002-11-21 | 2007-07-10 | New York Blood Center | Compounds for inhibition of HIV infection by blocking HIV entry |
EP1615895A4 (en) | 2003-04-03 | 2007-11-07 | Merck & Co Inc | SUBSTITUTED BIARYL PYRAZOLES AS SODIUM CHANNEL BLOCKERS |
WO2006012181A1 (en) * | 2004-06-24 | 2006-02-02 | Ksn Energies, Llc | Electrical impedance tomography to characterize tissue |
RU2007115900A (ru) | 2004-10-27 | 2008-11-10 | Дайити Санкио Компани, Лимитед (Jp) | Производные бензола, имеющие 2 или более заместителей |
PL1846106T3 (pl) * | 2005-01-31 | 2013-03-29 | Dong Wha Pharm Co Ltd | Kompozycja farmaceutyczna do leczenia nefropatii i zdrowa żywność zawierająca wyciągi z ziół |
AU2006257638A1 (en) | 2005-06-15 | 2006-12-21 | Pfizer Limited | Substituted arylpyrazoles |
EA200702497A1 (ru) | 2005-06-15 | 2008-06-30 | Пфайзер Лимитед | Замещенные арилпиразолы для применения против паразитов |
ES2525217T3 (es) | 2005-06-27 | 2014-12-19 | Exelixis Patent Company Llc | Moduladores de LXR basados en imidazol |
DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
CA2675511A1 (en) | 2006-10-10 | 2008-04-17 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
WO2009032249A1 (en) * | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
CA2720343A1 (en) | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
MX2011008952A (es) | 2009-02-26 | 2011-09-27 | Merck Sharp & Dohme | Activadores de guanilato ciclasa solubles. |
US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
-
2010
- 2010-02-22 MX MX2011008952A patent/MX2011008952A/es active IP Right Grant
- 2010-02-22 AU AU2010218224A patent/AU2010218224B2/en not_active Ceased
- 2010-02-22 WO PCT/US2010/024853 patent/WO2010099054A2/en active Application Filing
- 2010-02-22 JP JP2011552075A patent/JP5411300B2/ja not_active Expired - Fee Related
- 2010-02-22 RU RU2011138970/04A patent/RU2011138970A/ru not_active Application Discontinuation
- 2010-02-22 KR KR1020117022295A patent/KR20110133034A/ko not_active Application Discontinuation
- 2010-02-22 CA CA2753434A patent/CA2753434C/en not_active Expired - Fee Related
- 2010-02-22 CN CN2010800184490A patent/CN102414194A/zh active Pending
- 2010-02-22 BR BRPI1008793A patent/BRPI1008793A2/pt not_active IP Right Cessation
- 2010-02-22 EP EP10705728.3A patent/EP2401265B1/en active Active
- 2010-02-24 US US12/711,854 patent/US8507512B2/en active Active
- 2010-02-25 TW TW099105497A patent/TW201035077A/zh unknown
- 2010-02-25 AR ARP100100555A patent/AR075609A1/es not_active Application Discontinuation
-
2011
- 2011-08-09 IL IL214559A patent/IL214559A0/en unknown
- 2011-09-12 CO CO11117858A patent/CO6430463A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR075609A1 (es) | 2011-04-20 |
EP2401265A2 (en) | 2012-01-04 |
JP2012519169A (ja) | 2012-08-23 |
RU2011138970A (ru) | 2013-04-10 |
WO2010099054A3 (en) | 2010-10-21 |
CA2753434A1 (en) | 2010-09-02 |
EP2401265B1 (en) | 2016-09-14 |
AU2010218224B2 (en) | 2013-06-27 |
JP5411300B2 (ja) | 2014-02-12 |
CN102414194A (zh) | 2012-04-11 |
CA2753434C (en) | 2014-07-15 |
IL214559A0 (en) | 2011-09-27 |
CO6430463A2 (es) | 2012-04-30 |
US8507512B2 (en) | 2013-08-13 |
US20100216764A1 (en) | 2010-08-26 |
AU2010218224A1 (en) | 2011-09-08 |
TW201035077A (en) | 2010-10-01 |
BRPI1008793A2 (pt) | 2016-03-08 |
WO2010099054A2 (en) | 2010-09-02 |
KR20110133034A (ko) | 2011-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011008952A (es) | Activadores de guanilato ciclasa solubles. | |
TN2010000106A1 (en) | Soluble guanylate cyclase activators | |
WO2007117982A3 (en) | Organic compounds | |
PE20140630A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso | |
NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
WO2008076336A3 (en) | Imidazoles as aldosterone synthase inhibitors | |
CL2012003317A1 (es) | Compuestos derivados de 5,7-dihidro-6h-pirrolo[2,3-d]pirimidin-6-ona, moduladores de la produccion de guanosin monofosfato ciclico (cmpc); su composicion farmaceutica; utiles en el tratamiento de enfermedades cardiovasculares, disfuncion endotelial y diastolica, aterosclerosis, hipertension, trombosis, angina de pecho, entre otras. | |
PE20100559A1 (es) | Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla | |
CL2014000504A1 (es) | Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
EP2628727A3 (en) | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders | |
NZ596302A (en) | Aryl pyridine as aldosterone synthase inhibitors | |
MX2019005819A (es) | Preparacion y usos de acido obeticolico. | |
CY2016017I2 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
MX2010004576A (es) | Derivados de pirimidina novedosos. | |
TW200640914A (en) | Novel processes for the preparation of a benzofuran | |
EP2012766A4 (en) | JAK2 INHIBITION AS TREATMENT OF LUNG ARTERY HIGH PRESSURE | |
IL192208A0 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
FR2910230B3 (fr) | Methodes de biofertilisations pour ameliorer la stabilite des rendements de grandes cultures agronomiques. | |
WO2009053748A3 (en) | Novel crystalline forms | |
WO2010076810A3 (en) | A process for the preparation of gefitinib | |
IL210922A0 (en) | Treatment of pulmonary arterial hypertension | |
WO2008135795A3 (en) | Polymorphic forms of bosentan | |
WO2013059281A3 (en) | Processes for the preparation of novel benzimidazole derivatives | |
WO2010123545A3 (en) | Angiogenesis inhibitors | |
JP2011515406A5 (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME CORP.* |
|
HC | Change of company name or juridical status |
Owner name: MERCK SHARP & DOHME CORP.* |
|
FG | Grant or registration |